Drug Trial Radar · NCT02339155
Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
Last checked: Nov 20, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
573
Actual
Start
Feb 24, 2015
Primary completion
Jan 3, 2017
Study completion Jun 6, 2017
Sponsor
- Lead sponsor
- Emergent BioSolutionsIndustry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Jan 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study, as a post-marketing commitment to the Food and Drug Administration, is designed to detect the effect of raxibacumab on anthrax vaccine adsorbed (AVA) immunogenicity in a healthy volunteer population. This is a randomized, open-label, parallel group, two arm study to compare the immunogenicity of AVA at 4 weeks after the first AVA dose, when AVA is administered alone or concomitantly with raxibacumab. The study is planned to enroll approximately 30 to 534 subjects in up to 3 cohorts. The total duration of the study will be approximately 26 weeks. The dates reflect cohort 1.
Conditions
- Infections, Bacterial
Interventions
AVABiological
Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
RaxibacumabBiological
Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
DiphenhydramineDrug
Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of Geometric Mean Concentrations (GMC) of Anti-protective Antigen (PA) Antibody (Ab) at 4 Weeks (Day 29) After the First AVA Dose (Prior to the Third AVA Dose), Between the AVA Alone and the AVA With Raxibacumab Treatment GroupsTime frame: Day 29
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Edgewater, Florida
GSK Investigational Site
Overland Park, Kansas
GSK Investigational Site
Knoxville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.